There are currently 971 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and C S Mott Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
NCT06455826
Recruiting
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/11/2025
Locations: University of Michigan Kellogg Eye Center, Ann Arbor, Michigan
Conditions: Retinitis Pigmentosa 11, Retinal Degeneration, Eye Diseases, Retinal Disease, Retinal Dystrophies
Register for Updates
Home Exercise and Resiliency Training (Heart) Club
NCT05543733
Recruiting
The purpose of this research study is to evaluate the impact of a telemedicine-based structured home exercise program on frailty and exercise capacity in individuals with Fontan heart physiology, demonstrate that a telemedicine exercise program reduces socioeconomic and geographic barriers to access to exercise training, and to explore the impact of a structured exercise program on markers of Fontan-associated liver disease.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Fontan Physiology, Frailty
Register for Updates
Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
NCT05769348
Recruiting
This study investigates whether unilateral and bilateral non-invasive brain stimulation, given for 20 minutes/once per day for twenty days (M-F) can reduce migraine pain. Fourty patients will receive treatment (20 unilateral treatment, and 20 bilateral treatment), while twenty will receive a "sham" procedure. Another 20 Episodic Migraine patients will be recruited for the observational aim of the study which does not include brain stimulation.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Chronic Migraine
Register for Updates
Alcohol Screening and Preoperative Intervention Research Study - 2
NCT05783635
Recruiting
This sequential, multiple assignment, randomized trial will test treatments designed to reduce alcohol use before and after surgery to promote surgical health and long-term wellness.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
03/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Alcohol Drinking
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Michigan Clinical Research Institute PC, Ann Arbor, Michigan
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Lurbinectedin in FET-Fused Tumors
NCT05918640
Recruiting
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/06/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Register for Updates
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
NCT06580054
Recruiting
This phase II trial studies how well pembrolizumab works in treating patients with orbital (eye socket) and/or periorbital (surrounding the eye socket) cutaneous squamous cell cancer (cSCC) that has spread to nearby tissue or lymph nodes (locally advanced) or has come back after a period of improvement (recurrent). Skin cancers that are close to the eye or on the eyelid often have more genetic (heredity) changes than other types of cancers. This means that the deoxyribonucleic acid (DNA) (the bu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Register for Updates
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
NCT06785116
Recruiting
This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery. Eligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Register for Updates
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
NCT05722002
Recruiting
This trial is being completed to compare two commonly used options to treat pain after surgery. Participants that undergo gallbladder removal, hernia repair, and breast lump removal will be eligible to enroll. Eligible participants will be randomized to 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) plus acetaminophen or low dose opioids plus acetaminophen). It is anticipated that the NSAID group will have superior clinical outcomes and fewer side effects when comp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Surgery, Pain, Postoperative
Register for Updates
Effects of Myofascial Massage and Patient-therapist Communication Levels on Shoulder Muscle Properties in Breast Cancer Survivors with Myofascial Pain
NCT06679400
Recruiting
The objective of the proposed study is to assess how myofascial massage alters stiffness and microvascular perfusion of shoulder muscles and how these changes are influenced by patient-therapist interactions. The primary hypothesis is that stiffness of shoulder muscles will be decreased, and microvascular perfusion will be increased after a 30-minute myofascial massage, and that the addition of patient-therapist communication levels will result in greater changes with certain levels.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Pain, Myofacial
Register for Updates
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
NCT03523975
Recruiting
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Mantle Cell Lymphoma
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438, Ann Arbor, Michigan
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates